跳过导航
Planning for the Unpredictable in Health Care Supply Chains
Article

Planning for the Unpredictable in Health Care Supply Chains



Editorial Rating

8

Qualities

  • Applicable
  • Eye Opening
  • Visionary

Recommendation

The public was concerned about toilet paper scarcity, but medtech and biopharma companies had other shortages in mind. Would there be enough masks and gloves and other medical supplies to go around? What if manufacturers shut down or suppliers became inaccessible? The COVID-19 pandemic exposed fragility in the global supply chain, but medical supply vulnerabilities were among the scariest revelations of the pandemic. Biopharma and medtech companies can assess their supply chain resiliency using this report from the Boston Consulting Group.

Take-Aways

  • The pandemic revealed vulnerabilities in the supply chains for medical technology and biopharmaceuticals; requiring immediate action to improve resiliency.
  • Medtech and biopharma companies must evaluate resiliency indicators, then identify items for immediate action.
  • Improve supply chain resiliency with end-to-end transparency, increased regulatory involvement and a commitment to upskilling employees.

About the Authors

Megan DeFauw, Shana Topp, Bryan Head, Ben Aylor and Aaron Snyder are professionals with the Boston Consulting Group.


Comment on this summary or 开始讨论